CoImmune Announces Positive Results from Phase 1/2 Clinical Trial of Allogeneic CAR-CIK Cells in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia
Oral presentation at 63rd ASH Annual Meeting & Exposition shows that treatment based on company’s proprietary technology platform induced sustained responses without severe toxicities Company also announces presentation of preclinical proof-of-concept data in Acute Myeloid Leukemia DURHAM, N.C., Dec. 15, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer […]